Dr. Reddy’s Laboratories (NYSE:RDY) said today that the FDA approved its doxorubicin hydrochloride liposome injection for intravenous administration.
The liposomal formulation is a therapeutic-equivalent generic version of the chemotherapeutic, Doxil.
Get the full story at our sister site, Drug Delivery Business News.